Highlights of December 2018
- Lupin partners with AbbVie to develop, commercialize novel oncology drug with US$30 Million upfront.
- Prestige BioPharma Partners with Cipla to Market on Herceptin Biosimilar.
- Aurobindo Pharma arm enters pact to form JV in China with Luoxin.
- Roche taps Icagen in neuro drug discovery deal worth up to US$274 Million.
- ResMed to acquire connected inhaler developer Propeller Health for US$225 Million.
- Amgen pays US$50 Million for Molecular Partners’ preclinical bispecific.
- Innovent buys Chinese rights to Incyte drugs for US$40 Million upfront.
- Tetra, Shionogi ink US$40 Million pact on PDE4 drug for Alzheimer’s, fragile X.
- Swedish Biotage acquires U.S. based PhyNexus for US$21.5 Million.
- Bristol-Myers, H3 Biomedicine explore RNA splicing drugs for cancer.
- Mobidiag forms JV with Autobio to bring its infectious disease assays to China.
Updates at Aagami:
- Aagami to attend JPM week in San Francisco; Schedule full, with 40+ one-on-one global partnering related strategic meetings.
- Aagami team achieve stupendous success in the business trips organized in December 2018 for 2 clients.
- 2018 ends with a sparkle for Aagami, with happy clients and numerous assignments executed.
- In December 2018, Aagami completed 16 years, and to celebrate, is offering special pricing to its clients in 2019.
We wish you all a Very Happy and Successful 2019, and beyond!